Short Interest in Genmab A/S (OTCMKTS:GNMSF) Declines By 10.1%

Genmab A/S (OTCMKTS:GNMSF) was the recipient of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 76,300 shares, a decline of 10.1% from the October 15th total of 84,900 shares. Based on an average daily volume of 16,400 shares, the short-interest ratio is presently 4.7 days.

Genmab A/S Trading Down 0.9 %

GNMSF opened at $210.76 on Tuesday. The stock has a market capitalization of $13.78 billion, a P/E ratio of 20.45 and a beta of 1.07. The stock has a 50-day moving average price of $236.51 and a 200-day moving average price of $258.78. Genmab A/S has a 12-month low of $202.30 and a 12-month high of $334.33.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.